An open-label, multiple ascending dose study to determine the maximum tolerated dose of R1530 in patients with advanced solid tumors.

Trial Profile

An open-label, multiple ascending dose study to determine the maximum tolerated dose of R1530 in patients with advanced solid tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 23 May 2013

At a glance

  • Drugs R-1530 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 12 May 2009 Actual end date (1 Feb 2009) added as reported by ClinicalTrials.gov.
    • 18 Apr 2009 New source identified and integrated (Roche).
    • 18 Apr 2009 New source identified and integrated (Roche).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top